Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9261143 | 0.77 | ALDH1A1 (0.73) | KDM4EGLAATMKMT2AALDH1A1 | |
| SCHEMBL3420238 | 0.77 | KDM4E (0.64) | KDM4EGLAATMKMT2AALDH1A1 | |
| SCHEMBL31220944 | 0.76 | MAPT (0.46) | KDM4ESMN1; SMN2KMT2AALDH1A1MAPT | |
| SCHEMBL22902399 | 0.76 | KDM4E (0.62) | KDM4EGLAATMKMT2AALDH1A1 | |
| SCHEMBL9673024 | 0.75 | KDM4E (1.00) | KDM4EGLAATMKMT2AALDH1A1 | |
| SCHEMBL6137195 | 0.75 | MAPT (0.48) | SMN1; SMN2KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL4717450 | 0.74 | POLB (0.50) | KDM4EATMSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL5050015 | 0.74 | ALDH1A1 (0.53) | KDM4ESMN1; SMN2KMT2AALDH1A1MAPT | |
| SCHEMBL3212436 | 0.73 | MEN1 (0.47) | SMN1; SMN2KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL8832365 | 0.73 | ALDH1A1 (0.53) | KDM4EGLAATMSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128873-A1 | HETEROCYCLIC PYRIDINONE COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025128848-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025101598-A1 | BI-CYCLIC PYRIMIDINE COMPOUNDS, METHODS AND USES THEREOF | ZENO MANAGEMENT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-12286428-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-29 | — | — | US | disclosed |
| WO-2024233847-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-114423757-B | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-3999508-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3999508-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| EP-1124823-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1082324-A1 | IMIDAZOPYRIDINE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-2000064449-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-11-02 | — | — | WO | disclosed |
| US-6093717-A | A SERINE PROTEASE INHIBITOR PREVENTING CORONARY ARTERY DISEASE AND INHIBITING THROMBUS FORMATION IN BLOOD | MERCK & CO., INC. (US) | 2000-07-25 | — | — | US | disclosed |
| EP-1017383-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2000-07-12 | — | — | EP | disclosed |
| US-6087373-A | A SERINE PROTEASE INHIBITOR FOR PREVENTING OR TREATING UNSTABLE ANGINA, REFRACTORY ANGINA, MYOCARDIAL INFARCTION, TRANSIENT ISCHEMIC ATTACKS, ATRIAL FIBRILLATION, THROMBOTIC STROKE, EMBOLIC STROKE, DEEP VEIN THROMBOSIS | MERCK & CO., INC. (US) | 2000-07-11 | — | — | US | disclosed |
| WO-2000026210-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000026211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-1999061442-A1 | IMIDAZOPYRIDINE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999015169-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | KDM4E 2420/4885GLA 922/4885ATM 2698/4885 |
| US-12286428-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | IRAK4, IRAK1, IRAK3 | KDM4E 158/4885GLA 3720/4885ATM 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.